Overview

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
Phase:
Phase 1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated